Literature DB >> 2302511

T tube intubation in the management of seriously ill patients with oesophagopleural fistulae.

A R Naylor1, W S Walker, J Dark, E W Cameron.   

Abstract

Ten patients referred late with oesophagopleural fistulae were managed by T tube intubation of the oesophageal defect. Seven survived and six had radiographic evidence of closure of the defect. One patient who removed his T tube early was discharged to convalesce with a small oesophagocutaneous fistula. Three patients died as a consequence of pre-existing renal failure, upper gastrointestinal haemorrhage and adult respiratory distress syndrome. Patients presenting late with multisystem complications and ongoing sepsis secondary to oesophagopleural fistulae pose a major management problem. Our preliminary results suggest that T tube intubation offers a potential alternative to major surgical intervention, when more conservative measures have failed.

Entities:  

Mesh:

Year:  1990        PMID: 2302511     DOI: 10.1002/bjs.1800770114

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Delayed esophagopleural fistula after endoscopic injection sclerotherapy for esophageal varices: A case report.

Authors:  Mingliang Sui; Weibing Tang; Changjiang Wu; Jinhu Yang; Huiping Liu; Chaofa Huang; Xianzhu Hu; Damei Xia; Yadi Yang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

2.  Endoscopic T-tube placement in the management of lye-induced esophageal perforation: Case report of a safe treatment strategy.

Authors:  Mary Aisling McMahon; Fardod O'Kelly; Kheng Tian Lim; Narayanasamy Ravi; John Vincent Reynolds
Journal:  Patient Saf Surg       Date:  2009-08-14

Review 3.  The insidious presentation and challenging management of esophageal perforation following diagnostic and therapeutic interventions.

Authors:  Savvas Lampridis; Sofoklis Mitsos; Martin Hayward; David Lawrence; Nikolaos Panagiotopoulos
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.